Home Cytoskeletal Signaling Cardiac Myosin

Cardiac Myosin

Cytoskeletal Signaling

HSP (HSP90) Kinesin Microtubule Associated Integrin PAK Dynamin Glycoprotein MLCK TACC3 Gap-Junction Actin Myosin Arp2/3 Complex KSP Piezo Channel Tight Junction Protein
  • All (4)
  • Cardiac Myosin Inhibitors (2)
  • Cardiac Myosin Activator (1)
  • Cardiac Myosin Modulator (1)
  • New Cardiac Myosin Products
Cat.No. Product Name Information Product Use Citations Product Validations
S8861 Mavacamten (MYK-461) Mavacamten (MYK-461, SAR439152) is a small-molecule modulator of cardiac myosin that targets the underlying sarcomere hypercontractility of hypertrophic cardiomyopathy (HCM), one of the most prevalent heritable cardiovascular disorders.
Circulation, 2023, 147(25):1919-1932
Circulation, 2023, 147(25):1919-1932
Curr Protoc, 2023, 3(4):e744
S9948 Danicamtiv (MYK-491)

A novel cardiac myosin activator that enhances cardiomyocyte contraction, Danicamtiv (MYK-491, SAR 440181) is also known by this designation.
bioRxiv, 2024, 2024.10.09.617269
J Am Heart Assoc, 2023, 12(20):e030682
E4662 CK-586 CK-586(CK-4021586) is an inhibitor of cardiac myosin used to treat obstructive hypertrophic cardiomyopathy (oHCM). It effectively reduces left ventricular outflow tract obstruction (LVOTO) in a dose-dependent manner.
E1016 Aficamten (CK-274)

Aficamten (CK-274, CK 3773274) is a novel cardiac myosin inhibitor that reduces myocardial contractility in vitro and in vivo with an IC50 of 1.4 μM.
E4662 CK-586 CK-586(CK-4021586) is an inhibitor of cardiac myosin used to treat obstructive hypertrophic cardiomyopathy (oHCM). It effectively reduces left ventricular outflow tract obstruction (LVOTO) in a dose-dependent manner.
E1016 Aficamten (CK-274)

Aficamten (CK-274, CK 3773274) is a novel cardiac myosin inhibitor that reduces myocardial contractility in vitro and in vivo with an IC50 of 1.4 μM.
S9948 Danicamtiv (MYK-491)

A novel cardiac myosin activator that enhances cardiomyocyte contraction, Danicamtiv (MYK-491, SAR 440181) is also known by this designation.
bioRxiv, 2024, 2024.10.09.617269
J Am Heart Assoc, 2023, 12(20):e030682
S8861 Mavacamten (MYK-461) Mavacamten (MYK-461, SAR439152) is a small-molecule modulator of cardiac myosin that targets the underlying sarcomere hypercontractility of hypertrophic cardiomyopathy (HCM), one of the most prevalent heritable cardiovascular disorders.
Circulation, 2023, 147(25):1919-1932
Circulation, 2023, 147(25):1919-1932
Curr Protoc, 2023, 3(4):e744